ILMN Illumina (ILMN) Q3 FY25 earnings call
Illumina delivered a strong Q3 FY25, exceeding revenue and EPS guidance, driven by robust clinical growth and successful NovaSeq X adoption. The company returned to growth ex-China, expanded operating margins, and raised its full-year outlook despite ongoing challenges in China and muted research funding. Management remains focused on disciplined execution and multiomics expansion to achieve long-term financial targets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
ILMN operating KPIs by quarter
| KPI | Dec 2024 Q4 FY24 | Mar 2025 Q1 FY25 | This call Sep 2025 Q3 FY25 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|---|
| NovaSeq X placements | 91We placed 91 instruments during the quarter, bringing the installed base to 630.Source: earnings call transcript | 60+Our NovaSeq X instruments continue to perform well, exceeding our expectations with another quarter of over 60 placements in Q1, following more than 90 placements in Q4.Source: earnings call transcript | 55+In Q3, we had another strong quarter for the NovaSeq X with more than 55 instruments placed in line with our goal of 50 to 60 placements per quarter.Source: earnings call transcript | 95+Rest of World organic revenue grew 8.1%, above the high end of our guidance and demand for NovaSeq X remained high more than 3 years after launch with more than 95 placements in the quarter.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.